Table 1. . Demographics in Phase III studies SC1401 and SC1402.
| Demographics | SC1401 | SC1402 | ||
|---|---|---|---|---|
| Placebo (n = 485) | Sarecycline (n = 483) | Placebo (n = 515) | Sarecycline (n = 519) | |
| Mean age (years): | 19.8 | 19.7 | 19.7 | 20.3 |
| – 9–11 years, n (%) | 6 (1.2) | 4 (0.8) | 4 (0.8) | 7 (1.4) |
| – 12–17 years, n (%) | 235 (48.5) | 241 (49.9) | 256 (49.7) | 227 (43.7) |
| – 18+ years, n (%) | 244 (50.3) | 238 (49.3) | 255 (49.5) | 285 (54.9) |
| Race, n (%): | ||||
| – White | 377 (77.7) | 377 (78.1) | 391 (75.9) | 407 (78.4) |
| – Black or African–American | 79 (16.3) | 80 (16.6) | 76 (14.8) | 66 (12.7) |
| – Asian | 9 (1.9) | 11 (2.3) | 21 (4.1) | 23 (4.4) |
| – Mixed race | 14 (2.9) | 11 (2.3) | 15 (2.9) | 13 (2.3) |
| – Other | 6 (1.2) | 4 (0.9) | 12 (2.3) | 9 (1.7) |
| Ethnicity: Hispanic or Latino, n (%) | 143 (29.5) | 144 (29.8) | 122 (23.7) | 131 (25.2) |
| Gender, female/male (%) | 55.9/44.1 | 55.5/44.5 | 56.7/43.3 | 60.7/39.3 |